Teva Pharmaceutical Industries Limited

US$42.61As of Sun 8 Nov 2026, 12:00 UTC
NYSE:TEVAHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 0.33%
Div yield —
ROE 6.65%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.84
PE TTM 99.82
TSR TTM 108.06%
Mkt cap US$49.72B
ROIC 16.33%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$43
1.41%
(7.65%)
Hold 5|5|3|5|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.49
0.47
0.51
0.49
28.13%
13.82%
12.22%
9.74%
Revenue$B
3.405
3.607
3.529
3.558
8.43%
15.41%
11.64%
8.94%
Peers (US$49.72B)
Cap (US$)
PE
54.84B
64.97x
49.80B
37.66x
47.52B
40.70x
44.46B
70.61x
Capital
TTM
5Y
10Y
Leveragex
0.547
0.047
0.051
EBIT/Intx
0.120
0.176
0.175
Own earn%
(50.13)
(65.71)
(55.68)
Sh yield%
44.18
9.18
7.47
Owners
Insiders/Inst%
14.11
71.59
Short interest%
1.52
SBC / revenue%
2.07
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
0–4
$1 testx
0.1
Incr. ROIC%
8

Teva Pharmaceutical Industries Limited develops, manufactures, markets and distributes generic and other medicines and biopharmaceutical products in the United States, Europe, Israel and internationally, with a focus on CNS, respiratory and oncology, and also supplies active pharmaceutical ingredients, contract manufacturing services, out-licensed products to other pharmaceutical companies, and OTC products such as SUDOCREM.